Prasco

Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution

Retrieved on: 
Friday, November 18, 2022
Cerebral edema, Macular edema, Pharmacy, THA, Prasco Laboratories, Risk, Laboratory, Safety, Partnership, Iris, Pigment, Prescription, Lens (anatomy), Multimedia, Patient, Glaucoma, Ocular hypertension, Inflammation, Eyelash, Merck Sharp & Dohme Federal Credit Union, Authorized generics, General of the branch, Generic drug, Pharmaceutical industry, Prasco

MASON, Ohio, Nov. 18, 2022 /PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015%.

Key Points: 
  • MASON, Ohio, Nov. 18, 2022 /PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN (tafluprost ophthalmic solution) 0.0015%.
  • This is Prasco's first Authorized Generic launch in partnership with Tha Pharma, Inc.
    Prasco's Tafluprost Ophthalmic Solution 0.0015% is therapeutically equivalent to ZIOPTAN, marketed under the Prasco label, and will be widely available in U.S. pharmacies.
  • Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
  • The most innovative and trusted brand companies rely on Prasco to bring their products to the generic marketplace as Authorized Generics.